Nouscom technology platform is based on combining two potent immunotherapies: oncolytic virus specifically targeted to tumor with neoantigen loaded genetic cancer vaccine
The program is based on oncolytic viruses encoding immunomodulators that are detargeted from their natural receptors and retargeted to surface tumor antigens. They infect and kill only cancer cells, causing immunogenic cell death, recruitment of T cells at the tumor site and reactivation of exhausted T cells in the tumor micro-environment.
Endo-Vaccine encoding immunomodulators
breaks tolerance and primes/rescues cancer-specific immune response.
The program is based on high capacity novel adenovirus vectors derived from primates encoding long strings of cancer neoantigens, to induce and expand cancer and patient specific T cells. Adeno vectors induce long lasting central and effector memory T cells. We have developed a robust, and very fast manufacturing process for the assembly of over 100 neoatigens in a single Adeno vector and the parallel production of small quantities of each personalized vaccine.
Exo-Vaccine encoding neoantigens
boosts cancer-specific responses for sustained immunity.
We have fully-equipped, state-of-the-art laboratories and a GMP facility.Read more